1 |
Kwon, D. H., Hwangbo, H., Choi, E. O., Kim, M. Y., Ji, S. Y., Kim, K. I., Park, N. J., Kim, S. O., Hong, S. H., Park, C., Hwang, H. J., Jeong, J. S. and Choi, Y. H. 2018. Effects of Corni Fructus on testosterone-induced benign prostatic hyperplasia in sprague dawley rats. J. Life Sci. 28, 1507-1515.
DOI
|
2 |
Lee, S. J., Choi, H. R., Lee, J. H., Kwon, J. W., Lee, H. K., Jeong, J. T. and Lee, T. B. 2014. Effects of unripe black raspberry extracts on prostate cancer cell line and rat model of benign prostatic hyperplasia. J. Kor. Soc. Food Sci. Nutr. 43, 507-515.
DOI
|
3 |
Park, D. J., Kang, S. H. and Cho, Y. H. 2006. The antihyperplastic effect of oral catechin ingestion in a rat model of benign prostatic hyperplasia. Kor. J. Urol. 47, 1289-1293.
DOI
|
4 |
Park, H. S., Chang, N. S., Kim, E. J., Yun, H. N., Lee, H. J., Lee, B. E., Kim, H. H., Kwon, S. W. and Jeong, Y. J. 2004. Association between nutrient intakes and benign prostate hyperplasia. Kor. J. Nutr. 37, 801-808.
|
5 |
Roehrborn, C. G. 2008. Pathology of benign prostatic hyperplasia. Int. J. Impot. Res. 20, 11-18.
|
6 |
Shingnaisui, K., Dey, T., Manna, P. and Kalita, J. 2018. Therapeutic potentials of Houttuynia cordata Thunb. against inflammation and oxidative stress: A review. J. Ethnopharmacol. 220, 35-43.
DOI
|
7 |
Traish, A. M. 2012. 5α-reductases in human physiology: an unfolding story. Endocr. Pract. 18, 965-975.
DOI
|
8 |
Van, A. B., Barkin, J. and Elterman, D. S. 2015. Medical therapy for benign prostatic hyperplasia: a review. Can. J. Urol. 1, 7-17.
|
9 |
Woodard, T. J., Manigault, K. R., McBurrows, N. N., Wray, T. L. and Woodard, L. M. 2016. Management of benign pro-static hyperplasia in older adults. Consult. Pharm. 31, 412-424.
DOI
|
10 |
Andriole, G., Bruchovsky, N., Chung, L. W., Matsumoto, A. M., Rittmaster, R., Roehrborn, C., Russell, D. and Tindall, D. 2004. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 172, 1399-1403.
DOI
|
11 |
Bisson, J. F., Hidalgo, S., Rozan, P. and Messaoudi, M. 2007. Therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract, on experimentally induced prostate hyper plasia in Wistar-Unilever rats. J. Med. Food 10, 628-635.
DOI
|
12 |
Carson, C. and Rittmaster, R. 2003. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2-7.
DOI
|
13 |
Choi, Y. S., Lee, H. H., Lee, B. H. and Lee, S. Y. 1998. Effects of extracts of Houttuynia cordata Thunb on the level of lipids and lipid peroxidation in the liver and serum of cholesterol-fed rats. Kor. J. Plant. Res. 11, 173-178.
|
14 |
Foot, K. T. 2019. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J. Urol. 37, 1293-1296.
DOI
|
15 |
Huang, Y., Chen, H., Zhou, X., Wu, X., Hu, E. and Jiang, Z. 2017. Inhibition effects of chlorogenic acid on benign prostatic hyperplasia in mice. Euro. J. Pharmacol. 809, 191-195.
DOI
|
16 |
El-Demerdash, F. M., Yousef, M. I. and El-Naga, N. I. 2005. Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats. Food Chem. Toxicol. 43, 57-63.
DOI
|
17 |
Choi, H. M., Jung, Y. U., Park, J. B., Kim, H. L., Youn, D. H., Kang, J. W., Jeong, M. Y., Lee, J. H., Yang, W. M., Lee, S. G., Ahn, K. S. and Um, J. Y. 2016. Cinnamomi cortex (cinnamomum verum) suppresses testosterone-induced benign prostatic hyperplasia by regulating 5α-reductase. Sci. Rep. 6, 31906.
DOI
|
18 |
Choi, B. R., Kim, H. K., Soni, K. K., Karna, K. K., Lee, S. W., So, I. and Park, J. K. 2018. Additive effect of oral lDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model. Drug Des. Devel. Ther. 12, 1855-1863.
DOI
|
19 |
Mobley, D., Feibus, A. and Baum, N. 2015. Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Prostgrad. Med. 127, 301-307.
DOI
|
20 |
Nicholson, T. M. and Ricke, W. A. 2011. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82, 184-199.
DOI
|
21 |
Keam, S. J. and Scott, L. J. 2008. Dutasteride: a review of its use in the management of prostate disorders. Drugs 68, 463-485.
DOI
|
22 |
Langan, R. C. 2019. Benign prostatic hyperplasia. Prime. Care 26, 223-232.
DOI
|
23 |
Azzouni, F. and Mohler, J. 2012. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis. 15, 222-230.
DOI
|
24 |
Richard, A., H., Zhong, H. Z., Dai, W., Dai, Q. and Liao, S. 2002. Structure-activity relationships for inhibition of human 5α-reductases by polyphenols. Biochem. Pharmacol. 63, 1165-1176.
DOI
|
25 |
Kim, H. M., Han, S. B., Oh, G. T., Kim, Y. H., Hong, D. H., Hong, N. D. and Yoo, I. D. 1996. Stimulation of humoral and cell mediated immunity by polysaccharide from mushroom Phellinus linteus. Int. J. Immunopharmacol. 18, 295-303.
DOI
|
26 |
Steers, W. D. 2001. 5alpha-reductase activity in the prostate. Urology 58, 17-24.
DOI
|
27 |
Ventura, S., Olier, V. L., White, C. W., Xie, J. H., Haynes, J. M. and Exintaris, B. 2011. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br. J. Pharmacol. 163, 891-907.
DOI
|
28 |
Madersbacher, S., Sampson, N. and Culig, Z. 2019. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A Mini-Review. Gerontology 65, 458-464.
DOI
|
29 |
Moon, J. M., Sung, H. M., Jung, H. J., Seo, J. W. and Wee, J. H. 2017. In vivo evaluation of hot water extract of Acorus gramineus root against benign prostatic hyperplasia. BMC Complement. Altern. Med. 17, DOI:10.1186/s12906-017-1887-9.
DOI
|
30 |
Naresh, K. N., Aparna, B. and Veeresh, B. 2013. Protective effect of naringin on testosterone induced benign prostatic hyperplasia in rats. Intern. J. Pharm. Res. Scholars 2, 239-244
|